- There's news today that bluebird bio has suspended its gene therapy work on sickle cell disease because of two cases of cancer in its treatment population.
- Survival rates for bone marrow transplants in general have steadily improved over the years, and everyone knows that one of the rough parts is the pre-treatment.
- But that problem might or might not get solved in time to help out bluebird (or to quell the worries that other gene-therapy outfits might have who are also targeting that hematopoietic tissue).
For further details see:
Cancer And Gene Therapy